Conjunctivitis: Clinical Trials

81 trials for Conjunctivitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

64 completed, 9 withdrawn, 5 unknown, 1 active not recruiting. 81 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 481Completed 64, Withdrawn 9, Unknown 5, Active not recruiting 1, Not yet recruiting 1, Terminated 1

Follow Conjunctivitis: new trials by email Literature Review of Conjunctivitis trials Research Report on Conjunctivitis

Trials (filtered) newest first · largest first

All 81 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of the Impact of Oral Ivermectin on Musca Sorbens Flies, Putative Vector of Trachoma
Ivermectin - Survival of Flies Developing in Faecal Samples
Phase 4Not yet recruitingLondon School of Hygiene and Tropical Medicine122026-10-052026-10-30
Trachoma Elimination Study by Focused Antibiotic (TESFA)
Azithromycin mass treatment, Azithromycin targeted treatment - Trachoma
Phase 4WithdrawnEmory University2025-06-012025-07-16
Azithromycin Reduction to Reach Elimination of Trachoma B
Azithromycin - Trachoma
Phase 4WithdrawnUniversity of California, San Francisco2024-10-012026-03-13
Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya
Nasal Guide - Dry Eye, Keratoconjunctivitis Sicca
Phase 4CompletedOyster Point Pharma, Inc.302023-06-142025-05-06
Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction
NAAGA (N-acetyl-aspartyl-glutamate) 49 mg/mL, azelastine hydrochloride 0.05% - Allergic Conjunctivitis, Dry Eye Disease (DED)
Phase 4CompletedAzienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona1342023-04-212025-07-15
Enhancing the A in SAFE for Trachoma
Azithromycin for Routine Community-wide MDA, Two Additional Rounds of Azithromycin for Children, Azithromycin for Second Community-wide MDA - Trachoma
Phase 4CompletedEmory University346302022-05-042024-02-29
Kebele Elimination of Trachoma for Ocular Health
Azithromycin - Trachoma
Phase 4Active not recruitingUniversity of California, San Francisco3200002022-02-072025-10-23
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis
olopatadine hydrochloride ophthalmic solution 0.7%), Fluticasone Propionate, Tears Naturale - Allergic Conjunctivitis
Phase 4CompletedAndover Research Eye Institute612021-12-312022-09-02
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale - Allergic Conjunctivitis
Phase 4CompletedAndover Research Eye Institute582021-12-142022-05-03
Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin
Administration of Albendazole on Day 1, Administration of Ivermectin on Day 1, Administration of Azithromycin on Day 1 - Trachoma, Lymphatic Filariases
Phase 4CompletedLondon School of Hygiene and Tropical Medicine135112021-12-012022-08-19
The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance
Oxymetazoline hydrochloride 0.1% ophthalmic solution, Placebo - Ptosis, Eyelid, Conjunctiva Inflamed
Phase 4CompletedUniversity of Miami1142021-06-082023-04-24
Azithromycin Reduction to Reach Elimination of Trachoma
Azithromycin - Trachoma
Phase 4CompletedUniversity of California, San Francisco39312021-05-292026-03-25
Tolerability Comparison of Flarex to Lotemax SM
Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38% - Ocular Inflammation, Keratoconjunctivitis
Phase 4CompletedHarrow Inc402021-05-012026-09-22
Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment
Bepotastine Besilate 1.5% PF, Olopatadine Hydrochloride 0.2% BAK - Allergic Conjunctivitis
Phase 4CompletedLaboratorios Poen972021-03-102022-12-15
Effect of Cequa™ in Subjects With Dry Eye Disease
CequaTM (Cyclosporine 0.09%) ophthalmic solution - Dry Eye Disease
Phase 4CompletedSun Pharmaceutical Industries Limited1352020-06-292024-02-06
Manuka Eye Droops for Treatment of Allergy
Manuka honey - Allergic Conjunctivitis
Phase 4WithdrawnToyos Clinic2020-01-012020-10-09
Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease
Lifitegrast - Ocular Discomfort, Ocular Inflammation
Phase 4WithdrawnUniversity of Alabama at Birmingham2019-01-012019-05-17
Repository Corticotropin Injection in Keratoconjunctivitis Sicca
repository corticotropin injection - Keratoconjunctivitis Sicca
Phase 4WithdrawnUniversity of Alabama at Birmingham2018-11-012018-12-14
Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso
Azithromycin, Amoxicillin, Cotrimoxazole - Child Development
Phase 4CompletedUniversity of California, San Francisco2522017-07-042023-03-02
Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis
Hyaluronic acid 0.05% & Ectoine 2.0%, Olopatadine hydrochloride ophthalmic solution 0.1% - Conjunctivitis, Allergic, Conjunctivitis, Vernal
Phase 4UnknownMichael Marchand, MD422017-06-112022-10-26

Showing 20 of 81. Sign in to see all of them.

Narrower conditions

Conjunctivitis, Allergic (40)  ·  Trachoma (20)  ·  Dry Eye Syndromes (12)  ·  Keratoconjunctivitis Sicca (11)  ·  Chlamydia Infections (5)  ·  Bacterial Infections (3)  ·  Conjunctivitis, Bacterial (3)  ·  Elephantiasis, Filarial (2)  ·  Eye Diseases (2)  ·  Hypersensitivity (2)  ·  Infections (2)  ·  Keratoconjunctivitis (2)  ·  Adenoviridae Infections (1)  ·  Asthma (1)

Broader conditions

Conjunctival Diseases (81)  ·  Eye Diseases (79)  ·  Hypersensitivity, Immediate (40)  ·  Immune System Diseases (40)  ·  Hypersensitivity (38)  ·  Corneal Diseases (33)  ·  Eye Infections (24)  ·  Bacterial Infections and Mycoses (23)  ·  Eye Infections, Bacterial (23)  ·  Infections (23)  ·  Bacterial Infections (20)  ·  Chlamydiaceae Infections (20)  ·  Conjunctivitis, Bacterial (20)  ·  Gram-Negative Bacterial Infections (20)

Interventions

Olopatadine Hydrochloride (16)  ·  Azithromycin (12)  ·  Lubricant Eye Drops (7)  ·  Ophthalmic Solutions (7)  ·  Loteprednol Etabonate (6)  ·  alcaftadine (5)  ·  bepotastine besilate (5)  ·  Dexamethasone (3)  ·  Dextrans (3)  ·  Fluticasone (3)  ·  Hyaluronic Acid (3)  ·  Moxifloxacin (3)  ·  Carboxymethylcellulose Sodium (2)  ·  Cyclosporine (2)  ·  Ivermectin (2)

Sponsors

Alcon Research (12)  ·  University of California, San Francisco (10)  ·  Allergan (5)  ·  Johns Hopkins University (4)  ·  ORA, Inc. (4)  ·  Emory University (3)  ·  Hom, Milton M., OD, FAAO (3)  ·  London School of Hygiene and Tropical Medicine (3)  ·  Andover Research Eye Institute (2)  ·  Bausch & Lomb Incorporated (2)  ·  Laboratoires Thea (2)  ·  University of Alabama at Birmingham (2)  ·  Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona (1)  ·  Baylor College of Medicine (1)  ·  EV Clinical Trials (1)

Countries

United States (43)  ·  Ethiopia (6)  ·  United Kingdom (4)  ·  Niger (3)  ·  South Korea (3)  ·  Canada (2)  ·  France (2)  ·  Italy (2)  ·  Japan (2)  ·  Tanzania (2)  ·  Argentina (1)  ·  Burkina Faso (1)  ·  China (1)  ·  Democratic Republic of the Congo (1)  ·  Finland (1)

Top investigators

Tom Lietman, MD (3)  ·  Catherine Oldenburg, ScD, MPH (2)  ·  Elodie Lebas, RN (2)  ·  Julius Schachter, PhD (2)  ·  Kieran S O'Brien, MPH (2)  ·  Milton M Hom, OD FAAO (2)  ·  Paul Emerson, PhD (2)  ·  Sheila K West (2)  ·  Tarek Shazly, MD (2)  ·  Thomas M Lietman, MD (2)  ·  Tom M Lietman, MD (2)  ·  Abdou Amza, MD (1)  ·  Adisak Trinavarat, MD (1)  ·  Ahmad M Fahmy, O.D. (1)

Results publications

PMID 25260889, PMID 16905024, PMID 17585003, PMID 19127072, PMID 19302250, PMID 19329003, PMID 21072224, PMID 21685340, PMID 22095569, PMID 22180732, PMID 22192488, PMID 22545165, PMID 22736616, PMID 22953007, PMID 23326612, PMID 23392481, PMID 23785525, PMID 24433194, PMID 24621121, PMID 25002297, PMID 25083776, PMID 25407464, PMID 25858004, PMID 26302380, PMID 26489933, PMID 27956455, PMID 28351345, PMID 28402408, PMID 28893761, PMID 29088030, PMID 29260659, PMID 29561511, PMID 29897440, PMID 30014828, PMID 30106956, PMID 30151409, PMID 30419040, PMID 30515431, PMID 30689671, PMID 30895203, PMID 30950493, PMID 31166952, PMID 31237871, PMID 31362969, PMID 31589610, PMID 31796025, PMID 32556194, PMID 33407263, PMID 34559801, PMID 34967883

NIH funding

5UG1EY030833 (2), R01AI048789 (2), 1UG1EY028088 (1)